Skip Navigation

Reducing Animal Research at the U.S. Army Medical Research Institute of Chemical Defense

Maj. Randall E. Greenfield, chief, Comparative Medicine Division
Cindy A. Kronman, Research Operations Division
Col. David H. Moore deputy commander

U.S. Army Medical Research Institute of Chemical Defense
 3100 Ricketts Point Road
 Aberdeen Proving Ground, MD 21010-5424

The U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) at Aberdeen Proving Ground, Maryland, is the lead laboratory for executing the Department of Defense's medical chemical defense research program. The USAMRICD employs 141 permanent civilians and 55 military officers, and supplements this staff with National Research Council fellows, interns from the Oak Ridge Institute for Science and Education (ORISE)postgraduate internship program, and contract personnel. There are approximately 42 principal investigators, who carry out a research budget of over 16 million dollars. Their mission is to develop medical countermeasures against exposure to chemical warfare agents as well as against agents of biological origin. While the accomplishment of this research mission necessarily requires in vivo studies, in the last eleven years scientists at the USAMRICD have reduced the number of animals used in their research protocols by 92%.

These efforts to reduce the use of animals in research are part of a larger program initiated by the Department of Defense, and more specifically by the U.S. Army Medical Research and Material Command (USAMRMC), of which the USAMRICD is a subordinate unit. In 1992, the U.S. House of Representatives Committee on the Armed Services issued a report on the use of animals in DoD military experiments. The resulting action was the 1993 National Defense Authorization Act, requiring DoD to submit a comprehensive annual report on animal cost and use as well as in depth profiles of animal research and initiatives to promote alternatives to reduce, refine, and replace (the Three R's). In 1995, DoD issued directives and policies that updated and redefined its requirements for the care and use of animals in DoD-sponsored programs. In adopting the Three R's, the DoD also added a fourth, responsibility.

In 1993, the USAMRMC developed a management by objective program based on science and technology objectives, or STOs, with specific tasks under each objective. Among the major objectives established by the USAMRMC was one to develop reduction, refinement, and replacement strategies for the use of animals in research. The goal was to develop technologies that would incrementally reduce reliance on animal and human subject research and improve the experimental conditions using animals. Current objectives are to reduce reliance on animals in research by 25% by fiscal year 1999, using data from fiscal year 1991 as a baseline, and to introduce a minimum of one improvement per year in experimental protocols using animals.

The USAMRICD--AAALAC-accredited since 1984 and with an established animal care and use committee overseeing animal research since the late 1970's--was already in compliance with much of the Department of Defense directive when it was issued in 1995 and well on its way to meeting the goals of its Command's research objectives. Principal investigators at the USAMRICD have taken advantage of emerging technologies in the design of molecular modeling software and in the development and maintenance of cell culture models to meet the animal reduction goals of the USAMRMC. In addition, scientists, where possible, have adopted the use of less sentient animal species.

Computer modeling of the molecular structure of nerve agents, physiological enzymes, and neurotransmitters are used to predict and eventually determine how these chemical compounds interact at the molecular level. A test compound that inhibits acetylcholinesterase aging has also been studied via computer modeling to determine the specific molecular events that occur at the peripheral anionic site of AChE which subsequently prevents a potent AChE inhibitor, such as a nerve agent, from irreversibly binding to the acetylcholinesterase molecule. With this knowledge the most likely candidates for chemical intervention in the prevention or treatment of nerve agent exposure can be determined.

Currently, 17 cell lines or cell cultures are used in research at the USAMRICD. While they are used in research studies across the Institute's program, they have led particularly to a reduction of animal usage in the research programs on blistering chemical warfare agents. In efforts to evaluate the effects of blister agents, or vesicants, particularly sulfur mustard, and to develop medical countermeasures against such agents, alternatives to animals have proven particularly useful. Several cell line or culture systems, such as peripheral blood lymphocytes, human epidermal keratinocytes, and the HeLa, a human epithelial tumor line, have been adapted and developed by scientists at the USAMRICD into valuable models for studying vesicant injury. In addition, studies have used a commercial human skin equivalent model and skin biopsies from the Cooperative Human Tissue Network. The USAMRICD also has developed the technology to process and generate a human epidermal model, which possesses typical structural components of human epidermis in viva to include hemidesmosomes, anchoring filaments, and elements of a true basement membrane. The use of these alternative models has led especially to a decrease in the number of rodents required for these studies.

The USAMRICD also promotes the use of less sentinent or less regulated animal species. Researchers at the USAMRICD use the Aplysia californica, a large naked marine mollusk or gastropod with anterior sensory tenacles, commonly referred to as the sea hare or sea slug. The Aplysia californica possesses rather large and discrete neural ganglia, unique neural anatomy that make these invertebrate animals an excellent and widely used model for neural transmission and neurotoxin research. The USAMRICD acknowledges that in certain sulfur mustard experimental protocols, SKH-1 hairless mice are an appropriate substitute for the hairless guinea pig. The main histological feature of skin lesions produced in a SKH-1 hairless mouse following exposure to sulfur mustard is the formation of microblisters at the dermal-epidermal junction. Similar microblisters also occur in sulfur mustard lesions of hairless guinea pigs. Whereas laboratory mice are not subject to the Animal Welfare Act, provisions for their care and use are contained in the Guide for the Care and Use of Laboratory Animals.

Through these alternatives to animal research initiatives, the USAMRICD is three years ahead of schedule and has already exceeded the 25% percent reduction in the use of animals required by the USAMRMC's research objective. From fiscal year 1991 to fiscal year 1996, the Institute's reliance on animals in its research dropped by 68%. The most dramatic drop was in the use of rodents in research; ninety percent fewer rodents were used in research protocols in 1996 than were used in 1985. The number of publications resulting from research at the USAMRICD, however, has remained high and even increased slightly over the last several years. Approximately, 34% of the Institute's 1996 publications were a result of research in which no animals or less sentient animal species were used.

New ALTEX: 2/2018

ALTEX cover 51

Support ALTWEB, Make a Gift
Online Humane Science Course


Building a Better Epithelium: New Frontiers in 3D Conference
April 25, 2019
Cambridge, MA

CellTox 2019
May 7, 2019
Milano, Italy

Biosystems Engineering: Bioreactors and Cell Factories
May 12-17, 2019
Braunweld, Switzerland

ALTERTOX Academy Training:
In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhalation Toxicology
May 23-24, 2019
Neuchatel, Switzerland

6th Symposium on Social Housing of Laboratory Animals
June 3-4, 2019
Beltsville, Maryland

Society for In Vitro Biology Annual Meeting
June 8-12, 2019
Tampa, Florida

Upcoming: CAAT-Europe Information Day On Biology-inspired Microphysiological Systems (MPS) to Advance Medicines for Patients' Benefit
June 17, 2019
Berlin, Germany

ALTERTOX Academy Training:
PBPK Modeling and Quantitative In Vitro-In Vivo Extrapolation
October 3-4, 2019
Wageningen, Netherlands

ALTERTOX Academy Training:
Novel In Silico Models for Assessment of Cosmetics
October 17-18, 2019
Milan, Italy

ALTERTOX Academy Training:
In Vitro Lung Models
November 14-15, 2019
Geneva, Switzerland

Save the Date!
5th International Conference on Alternatives for Developmental Neurotoxicity (DNT) Testing
February 3-5, 2020
Konstanz, Germany

Full Listing of CAAT Programs
and Activities